Does Your Business Plan Have A Fatal Flaw?
Date: Wednesday, March 3rd, 2010
Time: 6:30 - 9pm
Location: 650 Page Mill Road, Palo Alto (WSGR)
Map: click for WSGR campus map
(Please note that this is a new location for BioE2E)
---------------------------------------------------------------------------------
Online registration: http://www.acteva.com/go/bioe2e
General admission: $25; $35 on site registration Advance registration deadline: March 1st, 2010, 5pm
Does Your Business Plan Have A Fatal Flaw?
We will discuss how to critically analyze and draft a plan for business with concrete examples from their extensive experience. Our panelists will focus on the critical analysis that must precede the details of writing and drafting a plan and will articulate the key issues necessary for a great business. Our panelists also will address the key issues that distinguish truly great opportunities from the run of the mill.
Come to learn how to identify the diamonds in the rough and present them in the manner to achieve maximum value!
Speakers:
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Intellikine Troy Wilson serves as the President and CEO and is a co-founder of Intellikine, a venture-backed company focused on developing small molecules for cancer treatment. Under his leadership, Intellikine has raised over 50 million dollars for its R&D. Dr. Wilson was formerly a co-founder and Chief Business Officer at Ambrx, a biotechnology company focused on the optimization of protein-based medicines using non-natural amino acids. He previously served as Vice President, Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, where he played a key role in the creation and launch of several spinout companies. Dr. Wilson received his Ph.D. in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.
Linda Rubinstein, Principal, RDJ Advisors
Ms. Rubinstein has over 20 years of experience as a life sciences industry executive and as an investment banker. She was the CFO of Solexa, Inc., a publicly traded company selling next generation genetic analysis systems. She raised over $100 million in equity financing to fund Solexa's transition from product development to commercialization and built the finance organization to scale with rapid growth and to support international operations. Ms. Rubinstein negotiated the sale of Solexa to Illumina for $600 million. Prior to Solexa, Ms. Rubinstein was the CFO of ChemoCentryx, Inc. She architected the financial strategy for a privately held biotech company in its evolution from early-stage discovery to clinical development. She also served on the executive and development committees, directed intellectual property and oversaw operations. Ms. Rubinstein had years of experience in investment banking. Most recently she was the Senior Vice President in the Global Healthcare Group of Lehman Brothers.
Second event in a new series:
This event is the second in a new BioE2E series: the BioE2E Biotech Entrepreneurs Program. Through a series of seminars, this program will discuss business, legal, and practical issues facing today's biotech entrepreneurs and provide them with guidance and resources to help them focus their ideas and business strategies.
This program will feature monthly seminars covering a wide range of topics including:
Important early steps in setting up your business Effective business plans Building your board of directors and board of advisors Protecting your technology University/Institut e licensing deals Financing strategies - Angels, VCs, and Corporates Term sheets Partnerships and corporate licensing Regulatory strategies Exits Organized and Sponsored by BioE2E and WSGR
